Continuous Intravenous Nimodipine Infusion With Ethanol as Carrier in Aneurysmal Subarachnoid Hemorrhage Does Not Result in Measurable Cerebral Ethanol Levels.

ABSTRACT: An unimpaired neurological evaluation is essential for detecting delayed cerebral ischemia (DCI) in aneurysmal subarachnoid hemorrhage (aSAH) patients. Nimodipine is currently the only drug approved for DCI prevention. Intravenous nimodipine infusion contains 23.7 vol% ethanol as an excipient, resulting in up to 45 g of ethanol being infused daily, which may interfere with neurological assessment. Therefore, we aimed to measure ethanol concentrations in plasma, cerebrospinal fluid (CSF), and brain parenchyma during the infusion of 0.5-2 mg of nimodipine per hour in aSAH patients to quantify the ethanol neuronal exposure. Ethanol concentrations were determined by headspace gas chromatography-flame ionization detection in plasma and CSF and we set out brain parenchyma measurement using cereb

SUBMITTER: Moser MM 

PROVIDER: S-EPMC12439008 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature